Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial

CALGARY, Alberta, Jan. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Resverlogix Corp. (Resverlogix or the "Company") (TSX:RVX) and the Resverlogix BETonMACE Clinical Steering Committee (CSC), represented by Professor Kausik Ray (Chair)... Biopharmaceuticals, Cardiology, FDA Resverlogix, Apabetalone, bromodomain, diabetes, coronary artery disease

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043388

Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news